Treatment of severe atopic dermatitis patients with cyclosporin A (CyA): The long-term safety and efficacy

Y. Kubota, S. Imayama, H. Miyahara, T. Tanahashi, Y. Uemura, Masutaka Furue

Research output: Contribution to journalArticle

Abstract

Data on the use of oral cyclosporin A (CyA) therapy for severe adult atopic dermatitis (AD) have accumulated since 1987, and CyA has a place in the long-term treatment of severe AD provided that appropriate patients are selected and careful monitoring is performed. We have treated with 30 severe AD patients (19 males and II females) refractory to systemic steroids since 1992, for 1-42 months (M) (mean 12.4M, 1~6M: 13, 7~12M: 6, 13~24M: 9, 25M~: 2). Fourteen of these patients have shown an improvement in their symptoms. Five subjects are still continuing the CyA treatment. Seven subjects were readministered with CyA at each relapse (intermittent therapy); four patients significantly improved, but 2 changed their treatment to topical steroid ointment therapy. Three patients did not want to continue this therapy and returned to systemic steroid therapy. An excebation of the eruptions was seen in one subject. The blood pressure increased slightly in one subject. Based on the present study, CyA was found to produce a rapid and highly significant improvement in 23 patients (76.6%). In addition, no serious side effects were observed even in the long-term therapy.

Original languageEnglish
Pages (from-to)271-278
Number of pages8
JournalNishinihon Journal of Dermatology
Volume61
Issue number3
Publication statusPublished - Jan 1 1999
Externally publishedYes

Fingerprint

Atopic Dermatitis
Cyclosporine
Safety
Therapeutics
Steroids
Ointments
Blood Pressure
Recurrence

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Treatment of severe atopic dermatitis patients with cyclosporin A (CyA) : The long-term safety and efficacy. / Kubota, Y.; Imayama, S.; Miyahara, H.; Tanahashi, T.; Uemura, Y.; Furue, Masutaka.

In: Nishinihon Journal of Dermatology, Vol. 61, No. 3, 01.01.1999, p. 271-278.

Research output: Contribution to journalArticle

Kubota, Y, Imayama, S, Miyahara, H, Tanahashi, T, Uemura, Y & Furue, M 1999, 'Treatment of severe atopic dermatitis patients with cyclosporin A (CyA): The long-term safety and efficacy', Nishinihon Journal of Dermatology, vol. 61, no. 3, pp. 271-278.
Kubota, Y. ; Imayama, S. ; Miyahara, H. ; Tanahashi, T. ; Uemura, Y. ; Furue, Masutaka. / Treatment of severe atopic dermatitis patients with cyclosporin A (CyA) : The long-term safety and efficacy. In: Nishinihon Journal of Dermatology. 1999 ; Vol. 61, No. 3. pp. 271-278.
@article{0e35af2bf8bd48988bc520887d2b1d51,
title = "Treatment of severe atopic dermatitis patients with cyclosporin A (CyA): The long-term safety and efficacy",
abstract = "Data on the use of oral cyclosporin A (CyA) therapy for severe adult atopic dermatitis (AD) have accumulated since 1987, and CyA has a place in the long-term treatment of severe AD provided that appropriate patients are selected and careful monitoring is performed. We have treated with 30 severe AD patients (19 males and II females) refractory to systemic steroids since 1992, for 1-42 months (M) (mean 12.4M, 1~6M: 13, 7~12M: 6, 13~24M: 9, 25M~: 2). Fourteen of these patients have shown an improvement in their symptoms. Five subjects are still continuing the CyA treatment. Seven subjects were readministered with CyA at each relapse (intermittent therapy); four patients significantly improved, but 2 changed their treatment to topical steroid ointment therapy. Three patients did not want to continue this therapy and returned to systemic steroid therapy. An excebation of the eruptions was seen in one subject. The blood pressure increased slightly in one subject. Based on the present study, CyA was found to produce a rapid and highly significant improvement in 23 patients (76.6{\%}). In addition, no serious side effects were observed even in the long-term therapy.",
author = "Y. Kubota and S. Imayama and H. Miyahara and T. Tanahashi and Y. Uemura and Masutaka Furue",
year = "1999",
month = "1",
day = "1",
language = "English",
volume = "61",
pages = "271--278",
journal = "Nishinihon Journal of Dermatology",
issn = "0386-9784",
publisher = "Kyushu University, Faculty of Science",
number = "3",

}

TY - JOUR

T1 - Treatment of severe atopic dermatitis patients with cyclosporin A (CyA)

T2 - The long-term safety and efficacy

AU - Kubota, Y.

AU - Imayama, S.

AU - Miyahara, H.

AU - Tanahashi, T.

AU - Uemura, Y.

AU - Furue, Masutaka

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Data on the use of oral cyclosporin A (CyA) therapy for severe adult atopic dermatitis (AD) have accumulated since 1987, and CyA has a place in the long-term treatment of severe AD provided that appropriate patients are selected and careful monitoring is performed. We have treated with 30 severe AD patients (19 males and II females) refractory to systemic steroids since 1992, for 1-42 months (M) (mean 12.4M, 1~6M: 13, 7~12M: 6, 13~24M: 9, 25M~: 2). Fourteen of these patients have shown an improvement in their symptoms. Five subjects are still continuing the CyA treatment. Seven subjects were readministered with CyA at each relapse (intermittent therapy); four patients significantly improved, but 2 changed their treatment to topical steroid ointment therapy. Three patients did not want to continue this therapy and returned to systemic steroid therapy. An excebation of the eruptions was seen in one subject. The blood pressure increased slightly in one subject. Based on the present study, CyA was found to produce a rapid and highly significant improvement in 23 patients (76.6%). In addition, no serious side effects were observed even in the long-term therapy.

AB - Data on the use of oral cyclosporin A (CyA) therapy for severe adult atopic dermatitis (AD) have accumulated since 1987, and CyA has a place in the long-term treatment of severe AD provided that appropriate patients are selected and careful monitoring is performed. We have treated with 30 severe AD patients (19 males and II females) refractory to systemic steroids since 1992, for 1-42 months (M) (mean 12.4M, 1~6M: 13, 7~12M: 6, 13~24M: 9, 25M~: 2). Fourteen of these patients have shown an improvement in their symptoms. Five subjects are still continuing the CyA treatment. Seven subjects were readministered with CyA at each relapse (intermittent therapy); four patients significantly improved, but 2 changed their treatment to topical steroid ointment therapy. Three patients did not want to continue this therapy and returned to systemic steroid therapy. An excebation of the eruptions was seen in one subject. The blood pressure increased slightly in one subject. Based on the present study, CyA was found to produce a rapid and highly significant improvement in 23 patients (76.6%). In addition, no serious side effects were observed even in the long-term therapy.

UR - http://www.scopus.com/inward/record.url?scp=0032975016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032975016&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0032975016

VL - 61

SP - 271

EP - 278

JO - Nishinihon Journal of Dermatology

JF - Nishinihon Journal of Dermatology

SN - 0386-9784

IS - 3

ER -